Saxenda (Liraglutide): The Original Weight-Loss GLP-1 (2026)

Saxenda is the original GLP-1 receptor agonist approved for chronic weight management. The active ingredient is liraglutide — the same molecule sold under Victoza for type 2 diabetes. Saxenda's claim to fame: it broke the path that Wegovy and Zepbound followed nearly a decade later.

So Saxenda still has a place in 2026 — when it's the right answer, what to expect, and how it compares to the newer weekly options.

What Saxenda is

Same molecule as Victoza (approved for T2D in 2010), just at the higher 3.0 mg/day dose for weight management.

How Saxenda works

Saxenda is a GLP-1 receptor agonist. It mimics the GLP-1 hormone the body releases after meals, doing what every drug in the class does:

• Slows gastric emptying — extends satiety
• Reduces appetite via central nervous system effects
• Stimulates glucose-dependent insulin release
• Suppresses glucagon

The shorter half-life (~13 hours) is why it's dosed daily, unlike the weekly options.

For mechanism details, see GLP-1 receptor agonists.

What the trials show

The pivotal trial: SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence), a 56-week study of 3,731 adults with BMI ≥27 plus a weight-related condition, or BMI ≥30.

Key results at the 3.0 mg/day dose:

Of patients who responded (lost ≥5% by 16 weeks), 85% maintained clinically meaningful weight loss at 56 weeks.

A 3-year SCALE extension study showed:

• 56% lost ≥5% body weight at year 1
• About half of those maintained the loss at year 3 on continued treatment

Dosing

Saxenda titration is weekly:

Each step is intended to manage gastrointestinal side effects. Most patients reach 3.0 mg within ~5 weeks.

Storage: Refrigerate unused pens (36-46°F) until expiration. Once in use, store at room temperature (59-86°F) or refrigerated, up to 30 days. Never freeze.

Missed dose: Take the next regularly scheduled dose at the usual time. Do not double dose.

Side effects

Same general GLP-1 profile, with daily dosing intensifying the early GI burden for some patients:

• Common: Nausea, vomiting, diarrhea, constipation, headache, fatigue, indigestion, low blood sugar (in T2D patients), injection- site reactions, dizziness
• Less common: Gallbladder issues, kidney function changes
• Rare: Pancreatitis, thyroid C-cell tumors (boxed warning, rodent data), severe allergic reactions

Full safety profile: GLP-1 side effects.

When Saxenda is the right answer

The newer weekly drugs (Wegovy, Zepbound) produce more weight loss on average. But Saxenda has real niches in 2026:

• Daily-injection preference. Some patients prefer a daily routine to a weekly cliff.
• Shorter half-life if you need to stop quickly. Liraglutide clears the body within 2-3 days; semaglutide and tirzepatide take weeks.
• Older patients or polypharmacy. Some prescribers prefer the predictability of a shorter-acting drug when titrating around other medications.
• Supply constraints. When Wegovy or Zepbound is on shortage, Saxenda may be more accessible.
• Pediatric approval. Saxenda is FDA-approved for adolescents (12-17 years) with obesity and body weight ≥132 lb.

Saxenda vs Wegovy

Both are Novo Nordisk GLP-1s for weight management:

For most adults seeking maximum weight loss, Wegovy is the stronger choice. Saxenda is the right call for the niches above.

Saxenda vs Zepbound

Zepbound substantially outperforms Saxenda on average weight loss.

Cost

• List price: ~$1,349/month
• With Novo Nordisk savings card + commercial insurance: as low as $25/copay (eligibility caps apply)
• Without insurance: Less aggressive direct-cash programs than for Wegovy; pricing varies by pharmacy

See GLP-1 cost and GLP-1 coupon.

Who shouldn't take Saxenda

• Personal or family history of medullary thyroid carcinoma or MEN-2
• Personal history of pancreatitis
• Severe gastroparesis
• Pregnancy or planning pregnancy
• Active eating disorder
• Type 1 diabetes (Saxenda is not appropriate)

FAQ

Is Saxenda the same as Victoza? Same active ingredient (liraglutide), different dose and indication. Saxenda goes to 3.0 mg/day for weight management; Victoza maxes at 1.8 mg/day for diabetes.

Is Saxenda a GLP-1? Yes — Saxenda is a GLP-1 receptor agonist.

How much weight will I lose on Saxenda? Average is about 8% body weight at the 3.0 mg dose over 56 weeks. Individual results vary.

Why is Saxenda dosed daily when Wegovy is weekly? Liraglutide has a much shorter half-life (~13 hours) than semaglutide (~7 days). Each is engineered for its specific pharmacokinetics.

Is Saxenda approved for teens? Yes — FDA-approved for adolescents 12-17 years with body weight ≥132 lb and obesity.

This article is for educational purposes only and is not medical advice. Discuss treatment decisions with a qualified healthcare professional.